Lysophosphatidic Acid Receptor 2 (LPAR2) Antibody (FITC)

Background

LPAR2 is a G protein-coupled receptor for lysophosphatidic acid (LPA), expressed predominantly in epithelial tissues, the gastrointestinal tract, and immune cells. LPAR2 activation triggers signaling through Gq, Gi, and G12/13 proteins, leading to phospholipase C (PLC) activation, calcium mobilization, and Rho-mediated cytoskeletal changes. LPAR2 regulates cell proliferation, migration, and survival, playing important roles in tissue repair, immune responses, and cancer progression. In wound healing, LPAR2 promotes epithelial cell migration and proliferation, aiding tissue regeneration. In cancer, LPAR2 signaling enhances tumor cell survival, invasion, and resistance to apoptosis, particularly in ovarian and gastrointestinal cancers. LPAR2 also modulates immune responses by regulating cytokine production and immune cell migration. Dysregulation of LPAR2 is associated with inflammatory diseases and cancer metastasis. Targeting LPAR2 with selective antagonists is being explored for treating cancers and inflammatory conditions, as it contributes to pathological cell growth, migration, and survival.